Citigroup’s Rallybio RLYB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-492
Closed -$2.7K 6322
2025
Q4
$2.7K Sell
492
-745
-60% -$3.83K ﹤0.01% 5402
2025
Q3
$4.94K Buy
+1,237
New +$5.2K ﹤0.01% 5232
2025
Q1
Sell
-306
Closed -$2.35K 5900
2024
Q4
$2.35K Buy
306
+299
+4,271% +$2.5K ﹤0.01% 5540
2024
Q3
$64 Sell
7
-2,587
-100% -$24.9K ﹤0.01% 5553
2024
Q2
$27.8K Buy
2,594
+1,800
+227% +$24.4K ﹤0.01% 4892
2024
Q1
$11.7K Sell
794
-910
-53% -$12.7K ﹤0.01% 5164
2023
Q4
$32.6K Buy
1,704
+1,695
+18,833% +$41.4K ﹤0.01% 4742
2023
Q3
$246 Sell
9
-1,132
-99% -$49K ﹤0.01% 5300
2023
Q2
$51.7K Buy
+1,141
New +$55.9K ﹤0.01% 4630
2023
Q1
Sell
-81
Closed -$4.27K 5808
2022
Q4
$4.27K Sell
81
-13
-14% -$767 ﹤0.01% 5074
2022
Q3
$11K Sell
94
-118
-56% -$10.5K ﹤0.01% 4962
2022
Q2
$13K Buy
212
+38
+22% +$2.85K ﹤0.01% 5243
2022
Q1
$10K Sell
174
-177
-50% -$14.6K ﹤0.01% 5543
2021
Q4
$27K Buy
351
+248
+241% +$28.9K ﹤0.01% 5308
2021
Q3
$14K Buy
+103
New +$12.1K ﹤0.01% 5381

Other funds holding RLYB

Citigroup's RLYB Position: Q1 2026 in Review

Citigroup sold out of Rallybio (RLYB) in Q1 2026, closing a stake of 492 shares — an estimated $2.7K sold.

Citigroup first reported a position in RLYB in Q3 2021 and held it in 15 quarters. The position peaked at $51.7K in Q2 2023. 38 funds tracked by Wall St. Rank hold RLYB as of Q1 2026.

  • Citigroup reported no remaining Rallybio position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 492 Rallybio shares in Q1 2026, an estimated $2.7K.
  • Citigroup first reported a position in Rallybio in Q3 2021 and held it in 15 quarters.
  • Citigroup's Rallybio position peaked at $51.7K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held Rallybio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.